Drugs / HLX35
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05442996 | Jan 2023 → Apr 2024 | cancer | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT05360381 | Jun 2022 → Oct 2024 | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05360381 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT05360381 ↗ |
| Target | EGFR | “A Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody” NCT05360381 ↗ |